Drugs / Vesnarinone
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00002337 | — | HIV infectious disease | Otsuka America Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT00002129 | — | HIV infectious disease | Otsuka America Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00002131 | — | HIV infectious disease, Kaposi's sarcoma | Otsuka America Pharmaceutical | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00002130 | — | HIV infectious disease | Otsuka America Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vesnarinone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002131 ↗ |
| Known as | Arkin z | ChEMBL registry synonym — accepted as the source's own label CHEMBL17423 ↗ |
| Known as | OPC-8212 | “A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons” NCT00002130 ↗ |
| Known as | Vesnarinona | ChEMBL registry synonym — accepted as the source's own label CHEMBL17423 ↗ |
| Modality | Small molecule | — CHEMBL17423 ↗ |
| Route | Oral | “oral vesnarinone” NCT00002129 ↗ |